Turn Therapeutics

Historical price data

Turn Therapeutics is advancing a pipeline of first-in-class, localized cytokine-modulating therapies, beginning with dermatologic inflammation. The company's mission is to deliver biologic-level efficacy precisely where disease occurs, avoiding the systemic side effects associated with injectable biologics. It has achieved regulatory validation with three FDA clearances for its proprietary wound and dermatology formulations, which support a capital-efficient business model. Turn's lead program, GX-03, is a topical modulator targeting IL-36 and other key cytokines for moderate-to-severe atopic dermatitis (eczema).

Patented platform for localized cytokine modulation via topical delivery, centered on the PermaFusion® drug delivery system and designed to target inflammatory pathways at the site of disease without systemic exposure.

In dermatology, Turn faces dominant systemic biologics and JAK inhibitors, and competition from other topical agents. Its key differentiation is targeting the IL-36 pathway topically with a non-systemic profile. In wound care, it competes in a fragmented market with its differentiated PermaFusion® technology.